VINFLUNINE & AREAS FOR IMPROVEMENT IN THE MANAGEMENT OF UROTHELIAL CARCINOMA – SUMMER 2013

Overview of Registration Trials Data in Urothelial Carcinoma In total, 450 patients were treated in two phase II trials and one phase III trial that together formed the basis for the registration of vinflunine monotherapy in urothelial carcinoma patients after failure of platinum-based therapy (see Table 1).1–3 Similar data were reported in the two phase […]

The potential role of vinflunine in sequential treatment strategies for urothelial carcinoma, in both the perioperative setting and maintenance therapy, will be highlighted below. Rationale for Perioperative Systematic Therapy in Bladder Cancer The natural history and evolution of urothelial carcinoma suggests that the study of perioperative systemic therapy may yield benefits (see Table 1),1–9 because […]

Standard Chemotherapy in ‘Fit’ Bladder Cancer Patients First-line treatment options in ‘fit’ bladder cancer patients who are able to receive platinum-based therapy include GC, paclitaxel/gemcitabine/cisplatin (PGC), methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) with or without granulocyte colony-stimulating factor (G-CSF), or high-dose (HD)-MVAC with G-CSF. The highest level of evidence and grade of recommendation is available […]

First-line Treatment of Unfit Bladder Cancer Patients – An Overview In the first-line setting treatment of unfit bladder cancer patients, a long list of small phase I, II and III trials investigating various combinations of chemotherapy regimens is available (see Table 1). Most data are on gemcitabine-based combinations, such as GCa, which is probably the […]

An overview of evidence on use and development of cytotoxic and targeted agents in the second-line setting after failure of a platinum-based regimen will be presented below. Additional considerations on the possible role of immunotherapy in bladder cancer are also discussed. Combinations of vinflunine with therapeutic agents that are already in use in bladder cancer […]